182 related articles for article (PubMed ID: 20138246)
1. Landscape phage fusion protein-mediated targeting of nanomedicines enhances their prostate tumor cell association and cytotoxic efficiency.
Jayanna PK; Bedi D; Gillespie JW; DeInnocentes P; Wang T; Torchilin VP; Bird RC; Petrenko VA
Nanomedicine; 2010 Aug; 6(4):538-46. PubMed ID: 20138246
[TBL] [Abstract][Full Text] [Related]
2. Enhanced binding and killing of target tumor cells by drug-loaded liposomes modified with tumor-specific phage fusion coat protein.
Wang T; D'Souza GG; Bedi D; Fagbohun OA; Potturi LP; Papahadjopoulos-Sternberg B; Petrenko VA; Torchilin VP
Nanomedicine (Lond); 2010 Jun; 5(4):563-74. PubMed ID: 20528452
[TBL] [Abstract][Full Text] [Related]
3. Peptide-conjugated nanoparticles for targeted imaging and therapy of prostate cancer.
Yeh CY; Hsiao JK; Wang YP; Lan CH; Wu HC
Biomaterials; 2016 Aug; 99():1-15. PubMed ID: 27209258
[TBL] [Abstract][Full Text] [Related]
4. Cytoplasmic delivery of liposomes into MCF-7 breast cancer cells mediated by cell-specific phage fusion coat protein.
Wang T; Yang S; Petrenko VA; Torchilin VP
Mol Pharm; 2010 Aug; 7(4):1149-58. PubMed ID: 20438086
[TBL] [Abstract][Full Text] [Related]
5. Landscape phage ligands for PC3 prostate carcinoma cells.
Jayanna PK; Bedi D; Deinnocentes P; Bird RC; Petrenko VA
Protein Eng Des Sel; 2010 Jun; 23(6):423-30. PubMed ID: 20185523
[TBL] [Abstract][Full Text] [Related]
6. Selection of pancreatic cancer cell-binding landscape phages and their use in development of anticancer nanomedicines.
Bedi D; Gillespie JW; Petrenko VA
Protein Eng Des Sel; 2014 Jul; 27(7):235-43. PubMed ID: 24899628
[TBL] [Abstract][Full Text] [Related]
7. Liposomes targeted by fusion phage proteins.
Jayanna PK; Torchilin VP; Petrenko VA
Nanomedicine; 2009 Mar; 5(1):83-9. PubMed ID: 18838343
[TBL] [Abstract][Full Text] [Related]
8. Enhanced tumor delivery and antitumor activity in vivo of liposomal doxorubicin modified with MCF-7-specific phage fusion protein.
Wang T; Hartner WC; Gillespie JW; Praveen KP; Yang S; Mei LA; Petrenko VA; Torchilin VP
Nanomedicine; 2014 Feb; 10(2):421-30. PubMed ID: 24028893
[TBL] [Abstract][Full Text] [Related]
9. On the mechanism of targeting of phage fusion protein-modified nanocarriers: only the binding peptide sequence matters.
Wang T; Kulkarni N; D'Souza GG; Petrenko VA; Torchilin VP
Mol Pharm; 2011 Oct; 8(5):1720-8. PubMed ID: 21675738
[TBL] [Abstract][Full Text] [Related]
10. From phage display to nanoparticle delivery: functionalizing liposomes with multivalent peptides improves targeting to a cancer biomarker.
Gray BP; Li S; Brown KC
Bioconjug Chem; 2013 Jan; 24(1):85-96. PubMed ID: 23186007
[TBL] [Abstract][Full Text] [Related]
11. Subtype-specific binding peptides enhance the therapeutic efficacy of nanomedicine in the treatment of ovarian cancer.
Shen YA; Liu CS; Chang YH; Chen PH; He CL; Wu HC; Chuang CM
Cancer Lett; 2015 Apr; 360(1):39-47. PubMed ID: 25661733
[TBL] [Abstract][Full Text] [Related]
12. Promiscuous tumor targeting phage proteins.
Gross AL; Gillespie JW; Petrenko VA
Protein Eng Des Sel; 2016 Mar; 29(3):93-103. PubMed ID: 26764410
[TBL] [Abstract][Full Text] [Related]
13. In vitro optimization of liposomal nanocarriers prepared from breast tumor cell specific phage fusion protein.
Wang T; Kulkarni N; Bedi D; D'Souza GG; Papahadjopoulos-Sternberg B; Petrenko VA; Torchilin VP
J Drug Target; 2011 Sep; 19(8):597-605. PubMed ID: 21275826
[TBL] [Abstract][Full Text] [Related]
14. A novel peptide enhances therapeutic efficacy of liposomal anti-cancer drugs in mice models of human lung cancer.
Chang DK; Lin CT; Wu CH; Wu HC
PLoS One; 2009; 4(1):e4171. PubMed ID: 19137069
[TBL] [Abstract][Full Text] [Related]
15. Liposomal nanomedicines in the treatment of prostate cancer.
Kroon J; Metselaar JM; Storm G; van der Pluijm G
Cancer Treat Rev; 2014 May; 40(4):578-84. PubMed ID: 24216226
[TBL] [Abstract][Full Text] [Related]
16. Incorporation of a selective sigma-2 receptor ligand enhances uptake of liposomes by multiple cancer cells.
Zhang Y; Huang Y; Zhang P; Gao X; Gibbs RB; Li S
Int J Nanomedicine; 2012; 7():4473-85. PubMed ID: 22927761
[TBL] [Abstract][Full Text] [Related]
17. Metastatic prostate cancer cell-specific phage-like particles as a targeted gene-delivery system.
Fagbohun OA; Kazmierczak RA; Petrenko VA; Eisenstark A
J Nanobiotechnology; 2013 Sep; 11():31. PubMed ID: 24059645
[TBL] [Abstract][Full Text] [Related]
18. Delivery of siRNA into breast cancer cells via phage fusion protein-targeted liposomes.
Bedi D; Musacchio T; Fagbohun OA; Gillespie JW; Deinnocentes P; Bird RC; Bookbinder L; Torchilin VP; Petrenko VA
Nanomedicine; 2011 Jun; 7(3):315-23. PubMed ID: 21050894
[TBL] [Abstract][Full Text] [Related]
19. A novel peptide probe for imaging and targeted delivery of liposomal doxorubicin to lung tumor.
He X; Na MH; Kim JS; Lee GY; Park JY; Hoffman AS; Nam JO; Han SE; Sim GY; Oh YK; Kim IS; Lee BH
Mol Pharm; 2011 Apr; 8(2):430-8. PubMed ID: 21222482
[TBL] [Abstract][Full Text] [Related]
20. Attaching the phage display-selected GLA peptide to liposomes: factors influencing target binding.
van Rooy I; Hennink WE; Storm G; Schiffelers RM; Mastrobattista E
Eur J Pharm Sci; 2012 Feb; 45(3):330-5. PubMed ID: 22155541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
